Research output per year
Research output per year
Fingerprint
Dive into the research topics where New Jersey Medical School (NJMS), Medicine, Global Tuberculosis Institute is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022–2024
Liang, R., Brust, J. C. M., Reed, C., Escuyer, V., Armstrong, D. T., Parrish, N., Valois, P., Rowlinson, M. C., Marinova-Petkova, A., Bisson, G. P., Labuda, S. M., Colon-Semidey, A., Haley, C. A., Ashkin, D., Peloquin, C. A., Lardizabal, A., Patrawalla, A., Cuenca, A., Haas, M. K. & Brostrom, R. & 9 others, , Jan 1 2026, In: Open Forum Infectious Diseases. 13, 1, ofaf786.Research output: Contribution to journal › Article › peer-review
Open Access1 Link opens in a new tab Scopus citations -
Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy
Baker, J. J., Nahar, R., Petroelje, B. K., Goswami, N. D. & Lardizabal, A. A., Aug 2023, In: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 32, 100376.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease
The BPaL Implementation Group, Oct 1 2023, In: Clinical Infectious Diseases. 77, 7, p. 1053-1062 10 p.Research output: Contribution to journal › Article › peer-review
Open Access40 Link opens in a new tab Scopus citations